Abdel-Qadir H, Singh SM, Pang A, et al. - This study’s findings demonstrate that the risk of stroke more than doubled in this study as men and women with atrial fibrillation (AF) but no other CHA2DS2-VASc risk factors aged from 66 to 74 years. These outcomes imply that anticoagulation therapy is more likely to benefit older individuals within this group of patients, whereas younger individuals are less likely to gain net clinical benefit from anticoagulation therapy.

• Researchers recruited a total of 16,351 individuals with AF (median [interquartile range] age, 70 [68-72] years), 8,352 (51.1%) were men; 6,314 individuals (38.6%) started anticoagulation therapy during follow-up.

• According to the findings, 1.1% was the overall 1-year stroke incidence among patients who did not receive anticoagulation therapy (95% CI, 1.0%-1.3%) and the incidence of death without stroke was 8.1% (95% CI, 7.7%-8.5%).

• The incidence of stroke was not significantly correlated with gender.

• It was shown that the calculated 1-year stroke risk was elevated with patient age from 66 years (0.7%; 95% CI, 0.5%-0.9%) to 74 years (1.7%; 95% CI, 1.3%-2.1%).